<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"Afirma GEC":1,
"ectopic parathyroid":1,
"fine-needle aspiration":2,
"thyroid":13,
"lncRNA":1,
"miRNA":1,
"ncRNA":1,
"transcription":1,
"translation":1,
"Breast cancer":11,
"Chemoresistance":2,
"MVP":1,
"Notch signaling pathway":1,
"Apoptosis":8,
"Invasion":6,
"Papillary thyroid cancer":5,
"Proliferation":8,
"ZNF703":1,
"siRNA":1,
"Cancer survivor":1,
"Estrogen replacement":1,
"Estrogen-progestin replacement":1,
"Gynecologic cancer":1,
"HRT":1,
"Hormone replacement therapy":1,
"MHT":1,
"Menopausal hormone therapy":1,
"Non-gynecologic cancer":1,
"Oncologic patient":1,
"Recurrence risk":1,
"Milan system":1,
"cytopathology":2,
"salivary gland":1,
"Endoscopic thyroidectomy":3,
"Papillary thyroid carcinoma":26,
"Robotic thyroidectomy":2,
"Laparoscopic ablation":1,
"Laparoscopic surgery":1,
"Liver resection":1,
"Local tumor control":1,
"Thyroid carcinoma":7,
"independent risk factor":1,
"survival":3,
"thyroid lobectomy":2,
"total thyroidectomy":1,
"equine endocrinology":1,
"horse":1,
"parathyroid adenoma":1,
"parathyroid imaging":1,
"parathyroidectomy":1,
"technetium Tc 99m sestamibi scan":1,
"Head and neck squamous cell carcinoma":1,
"Nasopharyngeal carcinoma":3,
"Oral squamous cell carcinoma":2,
"Radiotherapy":1,
"Secondary squamous cell carcinoma":1,
"Dissemination":1,
"Recurrence on the incision":1,
"Tumour seeding":1,
"Follicular adenoma":1,
"Follicular neoplasm":1,
"Follicular thyroid carcinoma":2,
"Thyroid cancer":28,
"Thyroid gland":2,
"Ultrasonography":3,
"contrast-enhanced ultrasound":2,
"lymph node metastasis":3,
"ultrasound":4,
"Merkel cell carcinoma":1,
"SATB2":1,
"differential diagnosis":2,
"immunohistochemistry":5,
"neuroendocrine":2,
"site of origin":1,
"transcription factor":1,
"Interstitial laser photocoagulation":1,
"Therapeutic outcome":1,
"Thyroid nodule":6,
"Graves’ disease":2,
"Graves’ orbitopathy":1,
"Outcome":1,
"Radioiodine":1,
"TSH-receptor antibody":1,
"Thyroidectomy":7,
"Areola approach":1,
"Central neck dissection":2,
"Safety":1,
"Trauma":1,
"Vestibular approach":1,
"Chemotherapy":3,
"Interstitial pneumonitis":1,
"Pegylated liposomal doxorubicin":1,
"hsa-miR139-5p and HNRNPF":1,
"miRNome sequencing":1,
"stroma infiltration":1,
"Antiemetics":1,
"Chemotherapy-induced nausea and vomiting":1,
"Guideline":2,
"Differentiated thyroid carcinoma":4,
"N1b":1,
"Prognostic value":1,
"TNM-7":1,
"TNM-8":1,
"CLT":1,
"Cancer":5,
"Hashimoto's":2,
"Incidental":1,
"ACR TI-RADS":1,
"ATA guidelines":1,
"thyroid nodules":7,
"Atypia of undetermined significance":1,
"Chronic lymphocytic thyroiditis":1,
"Thyroid malignancy":1,
"Thyroiditis":2,
"Chin numbness":1,
"Lip numbness":1,
"Mental nerve":1,
"Nerve injury":1,
"Thyroid surgery":2,
"Transoral endoscopic thyroidectomy":1,
"Graves' disease":2,
"Hyperthyroidism":3,
"Toxic multinodular goiter":1,
"Toxic solitary nodule":1,
"adjuvant":1,
"adverse effects":1,
"breast neoplasms":1,
"heart diseases":1,
"survivorship":1,
"Dihydroxyphenylalanine":1,
"Fluorodeoxyglucose":1,
"Medullary thyroid carcinoma":3,
"PET/CT":1,
"Somatostatin":1,
"cribriform-morular variant of papillary thyroid carcinoma":1,
"cytology":2,
"diagnosis":4,
"lung metastasis":1,
"APC":1,
"Gardner syndrome":1,
"WNT":2,
"familial adenomatosis polyposis":1,
"medulloblastoma":1,
"administrative database":1,
"epidemiology":2,
"gestational diabetes":1,
"pregnancy":1,
"Denosumab":2,
"Fibroblast growth factor 23 (FGF-23)":1,
"Hypercalcemia":1,
"Zoledronic acid":1,
"acid-base homeostasis":1,
"ion transporters":1,
"physiological and pathophysiological role":1,
"Pentose phosphate pathway":1,
"Reactive oxygen species":1,
"frail elderly":1,
"frailty":1,
"geriatric assessment":1,
"geriatric oncology":1,
"head and neck cancer":1,
"quality of life":3,
"Hashimoto":1,
"Lymphoma":2,
"MALT":1,
"Anti-cancer therapeutics":1,
"Mouse model":1,
"Preclinical testing":1,
"anaplastic thyroid cancer":1,
"chemoradiation":1,
"external beam radiotherapy":1,
"multimodality":1,
"radiation":3,
"trimodality":1,
"undifferentiated thyroid cancer":1,
"Epithelia-lmesenchymal transition (EMT)":1,
"Prostate cancer":2,
"circFoxo3":1,
"incidentaloma":1,
"overdiagnosis":1,
"screening":1,
"Lenvatinib":3,
"preclinical studies":1,
"tyrosine kinase inhibitor":2,
"Bethesda system":1,
"Thyroid aspiration cytology":1,
"cyst fluid only":1,
"foamy cells":1,
"Circular RNA":1,
"RAPGEF5":1,
"TXNIP":1,
"miR-27a-3p":1,
"miRNA sponge":1,
"matrix metalloproteinases-1":1,
"matrix metalloproteinases-2":1,
"neck dissection":2,
"tissue inhibitor of metalloproteinases-1":1,
"tissue inhibitor of metalloproteinases-2":1,
"Cordectomy":1,
"Difficult exposure":1,
"Glottic cancer":1,
"Glottoplasty":1,
"Laser":1,
"Thyroplasty":1,
"DCIS":1,
"Duct abnormalities":1,
"Non-mass abnormalities":1,
"Clinical behaviors":1,
"DTC":1,
"FTC":1,
"PTC":2,
"TERT":2,
"lymph node ratio":1,
"lymph node yield":1,
"persistent thyroid cancer":1,
"surgical quality":1,
"Papillary thyroid carcinoma (PTC)":3,
"SOCS1":1,
"STAT3 activation":1,
"TRIM14":1,
"fine-needle aspiration biopsy":2,
"histopathology":1,
"radioactive iodine":2,
"classification":2,
"malignancy":3,
"microRNA":3,
"mutation analysis":1,
"LncRNA FOXD3-AS1":1,
"MiR-296-5p":1,
"Mobility":1,
"SOX2":1,
"circ_0005273":1,
"miR-1183":1,
"progression":2,
"Thy terminology":1,
"United Kingdom":1,
"meta-analysis":1,
"risk of malignancy":1,
"thyroid fine-needle aspiration cytology (FNAC)":1,
"Molecular testing":1,
"Oncocytic variant":1,
"HOXA11-AS":1,
"YBX2":1,
"miR-98-5p":1,
"Frozen section":1,
"Thyroid neoplasm":2,
"eta-analysis":1,
"Endocrinology":1,
"Nuclear medicine":1,
"PET":1,
"Predictive":1,
"Prognostic":1,
"Inflammatory response":1,
"Oxidative stress":1,
"PTPN2":1,
"Hürthle cell":1,
"atypia of undetermined significance (AUS)":2,
"fine-needle aspiration (FNA)":1,
"follicular lesion of undetermined significance (FLUS)":2,
"malignancy risk":1,
"multinodularity":1,
"Japan":1,
"Multivariate statistical method":1,
"New hotspot panel":1,
"Next generation sequencing":1,
"Risk score":1,
"Anaplastic thyroid carcinoma":8,
"Antiangiogenesis":1,
"Bevacizumab":1,
"Mitochondrial targeting":1,
"Phase-transformation":1,
"Sequential targeting":1,
"Cell vitality":1,
"EMT":3,
"GCGR":1,
"P38/ERK":1,
"Machine learning":1,
"Magnetic resonance imaging":3,
"Radiomics":1,
"GPER":1,
"GPER1":1,
"GPR30":1,
"Active surveillance":1,
"BRAF V600E mutation":1,
"Papillary thyroid microcarcinoma":3,
"Prognosis":8,
"Risk stratification":2,
"Family cancer history":1,
"head neck squamous cell carcinoma":1,
"matched-pair study":1,
"tongue squamous cell carcinoma":1,
"autoimmunity":1,
"thyroid hormone":1,
"thyroid hormone metabolism and transport":1,
"thyroid hormone receptors":1,
"clinical practice guidelines":1,
"survey":1,
"T3b":1,
"extrathyroidal extension":1,
"papillary thyroid carcinomas":1,
"prognostic factors":1,
"Fukushima Daiichi Nuclear Power Plant accident":1,
"Fukushima Health Management Survey":1,
"thyroid ultrasound examination":1,
"bioinformatics":3,
"data mining":1,
"endocrine surgery":1,
"intraoperative nerve monitoring":1,
"recurrent laryngeal nerve":1,
"risk factor":2,
"surgery":4,
"radioiodine therapy":2,
"thyroid radioactive iodine uptake":1,
"LAG3":1,
"PD-1":1,
"Synergistic inhibition":1,
"Triple-negative breast cancer":1,
"Tumour infiltrating lymphocytes":1,
"ERK pathway":1,
"MEK-ERK inhibitor":1,
"Selenium":1,
"U0126":1,
"thyroid adenoma":1,
"thyroid neoplasms":5,
"thyroid stimulating hormone":1,
"thyrotropin":1,
"Forkhead box transcription factor M1":1,
"migration":6,
"thyroid papillary carcinoma":1,
"integrated analysis":1,
"key genes":1,
"microarray":2,
"CD24":1,
"CD44":1,
"cancer stem cell":1,
"BRAF mutation":2,
"recurrence":1,
"Akt/mammalian target of rapamycin signaling":1,
"medullary thyroid cancer":3,
"zinc finger protein 703":1,
"cyclin-dependent kinase":1,
"long noncoding RNA 00511":1,
"Chemosensitivity":1,
"Exosome":1,
"Hepatocellular carcinoma":3,
"Mesenchymal stem cell":1,
"miR-199a-3p":1,
"False-negative":1,
"False-positive":1,
"Fine-needle aspiration cytology (FNAC)":1,
"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)":1,
"2A típusú multiplex endokrin neoplasia szindróma":1,
"genetic testing":1,
"genetikai vizsgálat":1,
"medullaris pajzsmirigydaganat":1,
"multiple endocrine neoplasia type 2A":1,
"phaeochromocytoma":1,
"primary hyperparathyroidism":1,
"primer hyperparathyreosis":1,
"miR-383-5p":1,
"Korea":1,
"occupations":1,
"socioeconomic factors":1,
"NEK kinase family":1,
"NEK1":1,
"NEK3":1,
"NEK5":1,
"Tissue mirco array":1,
"Metformin":1,
"NSCLC":1,
"Snail":1,
"YAP":1,
"miR-381":1,
"Auto-fluorescence":1,
"Near-infrared":1,
"Parathyroid":1,
"NF-κB pathway":1,
"miR-145":1,
"progression-free survival":1,
"radioiodine-refractory differentiated thyroid carcinoma":1,
"CdTe":1,
"Coded aperture":1,
"Compact gamma camera":1,
"Medipix2":1,
"Radioguided surgery":1,
"Timepix":1,
"Guidelines":1,
"Size threshold":1,
"Thyroid imaging reporting and data system":1,
"Adrenal insufficiency":1,
"Adrenocorticotropic hormone deficiency":1,
"Immunotherapy":2,
"Pembrolizumab":1,
"Programmed cell death 1":1,
"Chromogenic Multiplex immunohistochemistry":1,
"Chromogenic quadruplex for NSCLC diagnostics":1,
"Non-small cell Lung carcinoma (NSCLC)":1,
"CNV":1,
"TCGA":1,
"prognostic markers":1,
"RCC":1,
"WHO":1,
"klasszifikáció":1,
"renal cell carcinoma":1,
"vesesejtes carcinoma":1,
"Intensity modulated proton therapy":1,
"Lymphoma cancer":1,
"NTCP":1,
"RapidArc":1,
"Seconday cancer risk estimate":1,
"VMAT":1,
"IODINE RADIOISOTOPES":1,
"MODELS, ECONOMIC":1,
"SORAFENIB":1,
"SYSTEMATIC REVIEW":1,
"THERAPEUTIC USE":1,
"Braf":1,
"Capsular invasion":1,
"Cáncer de tiroides":1,
"Inmunohistoquímica":1,
"Invasión capsular":1,
"Invasión vascular":1,
"Molecular pathology":1,
"Non-invasive follicular tumor with papillary-like nuclear features":1,
"Patología molecular":1,
"RAS":1,
"TP53":1,
"Tumor folicular no invasivo con rasgos nucleares de tipo papilar":1,
"Vascular invasion":1,
"AhR":1,
"SLUG":1,
"cell migration and invasiveness":1,
"STAT3":1,
"cancer stem cells":1,
"cell proliferation":2,
"cisplatin":1,
"curcumin":1,
"Level VII":1,
"Lymph node dissection":1,
"Video-assisted approach":1,
"Thymic enlargement":1,
"Thymus":1,
"Thyroglobulin":2,
"Thyroid follicular tumor":1,
"True thymic hyperplasia":1,
"14-3-3 ε/γ":1,
"Adaptor protein":1,
"Cell growth":1,
"LNK":1,
"Joinpoint regression analysis":1,
"histology":1,
"incidence":1,
"mortality":1,
"net survival":1,
"population-based study":1,
"registries":1,
"survival analysis":1,
"trends":1,
"functional screening":1,
"non-oncogene addiction":1,
"non-oncogenes":1,
"therapeutic targets":1,
"tumor vulnerabilities":1,
"Membrane-based liquid-based preparation technique":1,
"Sedimentation liquid-based preparation technique":1,
"Thyroid fine needle aspiration cytology (FNAC)":1,
"131I radioiodine":1,
"differentiated thyroid cancer":1,
"over and underestimated values":1,
"radiation absorbed dose":1,
"C634R":1,
"RET gene mutation":1,
"type 2 multiple endocrine neoplasia":1,
"False-positive finding":1,
"iodine-131":1,
"radioiodine scintigraphy":1,
"radioiodine single-photon emission computed tomography/computed tomography":1,
"retroperitoneal cysts":1,
"BRAF V600E":2,
"I -131 treatment":1,
"Thyroid function":1,
"ARID1A mutation":1,
"BRCA1 mutation":1,
"Glioblastoma":1,
"Metastasis":2,
"Mismatch repair deficiency":1,
"Temozolomide":1,
"Treatment resistance":1,
"papillary carcinoma prognosis":1,
"papillary microcarcinoma":1,
"thyroid capsule":1,
"tumor diameter":1,
"tumor location":1,
"tumor origin":1,
"Biopsy, Fine-Needle":1,
"Core needle biopsy":1,
"Case report":2,
"Hepatic metastases":1,
"Neuroendocrine tumor":1,
"Treatment":2,
"Circ-VRK1":1,
"cell activities":1,
"clinicopathological features":1,
"SMAC/DIABLO":1,
"TUSC2":1,
"Hashimoto’s thyroiditis":1,
"IgG":1,
"N-glycosylation":1,
"antibody-dependent cell-mediated cytotoxicity (ADCC)":1,
"complement-dependent cyttoxicity (CDC)":1,
"sialylation":1,
"environmental exposure":1,
"thyroid health":1,
"uranium":1,
"Papillary carcinoma":1,
"Solid variant":1,
"Anatomical variations":1,
"Carcinome nasopharyngé":1,
"Dosimetry":1,
"Dosimétrie":1,
"Glandes":1,
"Glands":1,
"Intensity modulated radiation therapy":1,
"Modifications anatomiques":1,
"Radiothérapie conformationnelle avec modulation d’intensité":1,
"Endoscopy":1,
"Scarring":1,
"DNA methylation":2,
"biomarkers":2,
"long non-coding RNAs":1,
"Glycolysis":1,
"HIF-1α":1,
"PKM2":1,
"PPAR-γ":1,
"Simvastatin":1,
"Sorafenib resistance":1,
"SPECT/CT imaging":1,
"antisense therapy":1,
"diagnosis and treatment integration":1,
"WT1-AS":1,
"miR-203":1,
"survivin":1,
"combretastatin A4 phosphate (CA4P)":1,
"contrast agents (CAs)":1,
"hepatocellular carcinoma (HCC)":1,
"imaging biomarker":1,
"liver cancer":1,
"magnetic resonance imaging (MRI)":1,
"therapeutic response":1,
"vascular disrupting agents (VDAs)":1,
"computed tomography":1,
"fine needle aspiration cytology":2,
"focus number":1,
"predictivity":1,
"3q26":1,
"GWAS":1,
"LRRC34":1,
"RANBP1":1,
"extension of thyroidectomy":1,
"personalised medicine":1,
"thyroid lobectomy (TL)":1,
"total thyroidectomy (TT)":1,
"Anaplastic thyroid cancer (ATC)":1,
"in vitro studies":1,
"in vivo studies":1,
"molecular pathways":1,
"targeted drugs":1,
"Intraoperative neuromonitoring":1,
"recurrent laryngeal nerve (RLN)":1,
"vocal cord palsy":1,
"Follicular carcinoma":1,
"follicular microcarcinoma":1,
"follicular tumor":1,
"RET":1,
"cysteine":1,
"peptide":1,
"Hashimoto thyroiditis":1,
"Marginal zone B-cell lymphoma":1,
"Mucosa-associated lymphoid tissue":1,
"genomics":1,
"mRNA":1,
"thyroid incidentalomas":1,
"Goiter":1,
"point of care":1,
"thyroid ultrasound":1,
"Grade Groups":1,
"pathological T stage":1,
"prostatectomy":1,
"thyroid hormones":1,
"triiodothyronine":1,
"tumor percentage involvement":1,
"young adults":1,
"Central lymph node dissection":2,
"Prophylactic":1,
"PROX1":1,
"lymphatic factors":1,
"thyroid cancers":1,
"detection rates":1,
"influencing factors":1,
"collision tumor":1,
"follicular thyroid cancer":1,
"FGF5":1,
"miR-188-5p":1,
"Biopsy":1,
"DICER1 protein":1,
"Epithelial neoplasm":1,
"Fine-needle":1,
"Human":1,
"Teratoma":1,
"Outcome modelling":1,
"Secondary malignancies":1,
"Knock-in":1,
"Transgenic mouse model":1,
"c-Myc":1,
"CSCC":1,
"PDCD5":1,
"miR-766":1,
"ceramide":1,
"glucosylceramide":1,
"motility":1,
"Nivolumab":1,
"immune checkpoint inhibitor":1,
"metastatic thyroid cancer":1,
"papillary thyroid":1,
"partial response":1,
"fine-needle aspiration cytology":1,
"rhabdoid phenotype":1,
"Hypocalcemia":1,
"Postoperative Complications":1,
"conventional ultrasound":1,
"petal-like calcifications":1,
"Conventional open thyroidectomy":1,
"Propensity score matching":1,
"Robotic-assisted thyroidectomy":1,
"BRAF inhibitor":1,
"MEK inhibitor":1,
"TERT promoter mutation":1,
"Child":1,
"Parathyroid carcinoma":1,
"Positron emission tomography of methionine":1,
"high-volume":1,
"ipsilateral prophylactic central lymph node dissection":1,
"lateral lymph node dissection":1,
"lymph node metastases":1,
"lymph nodes posterior to the right recurrent laryngeal nerve":1,
"prophylactic lymph node dissection":1,
"thyroid surgeon":1,
"GOLPH3":1,
"LINC00657":1,
"breast carcinoma":1,
"miR-590-3p":1,
"distant metastases":1,
"gene expression profile":1,
"Second lung cancer":1,
"Differentiated":1,
"TSH-releasing hormone":1,
"inappropriate secretion of thyroid-stimulating hormone":1,
"mixed gangliocytoma-adenoma":1,
"neuroendocrine neoplasm":1,
"pituitary gangliocytoma":1,
"thyroid-stimulating hormone":1,
"COVID-19":1,
"Epicenter":1,
"Psychological status":1,
"anlotinib":1,
"clinical trial":1,
"receptor tyrosine kinase inhibitor":1,
"safety management":1,
"vascular endothelial growth factor receptor":1,
"FDG-PET/CT scan":1,
"lung adenocarcinoma":1,
"metastatic carcinoma":1,
"JAK3":1,
"Next-generation sequencing":1,
"RAS mutation":1,
"Struma ovarii":1,
"Capsaicin":1,
"Mitochondrial calcium overload":1,
"TRPV1":1,
"Martinique Principles":1,
"Recommendations":1,
"RFS":1,
"TPC":1,
"nomogram":1,
"signature":1,
"Image interpretation":1,
"Mediastinum":1,
"Neoplasm":1,
"Multifocality":1,
"Recurrence-free survival":1,
"Benfluralin":1,
"Human relevance":1,
"Phenobarbital":1,
"Thyroid MOA":1,
"Thyroid carcinogenicity":1,
"Frozen section examination":1,
"Personalized medicine":1,
"Personalized surgery":1,
"thyroglossal cyst":1,
"thyroglossal duct cyst carcinoma":1,
"Psammoma Bodies":1,
"chemical composition":1,
"pathological micro-calcifications":1,
"glottic morphology":1,
"laryngeal function reconstruction":1,
"partial laryngectomy":1,
"pedicled sternohyoid muscle flap":1,
"spiral CT":1,
"SOX18":1,
"β-catenin":1,
"Psoriasis":1,
"anti TNF α agents":1,
"granuloma annulare":1,
"paradoxical reaction":1,
"Advanced thyroid cancer":1,
"Cutaneous metastases":1,
"Electrochemotherapy":1,
"Copy number variations":1,
"HCC":2,
"PRL-3":1,
"Phosphatase":1,
"TGFB1":1,
"I-131":1,
"radioiodine scan":1,
"tumor sink effect":1,
"fine-needle washout":1,
"immunoassays":1,
"rheumatoid factor":1,
"thyroglobulin auto-antibodies":1,
"TBX3":1,
"USP7":1,
"p57(KIP2)":1,
"atrial fibrillation":1,
"GEO":1,
"expression profiling":1,
"protein-protein interaction":1,
"FOXP1":1,
"hsa_circ_104566":1,
"miR-338-3p":1,
"Malignancy degree":1,
"Mir-146b":1,
"Mir-221":1,
"Thyroid carcinoma tissues":1,
"feasibility studies":1,
"forecasting":1,
"lymphatic metastasis":1,
"Pheochromocytoma":1,
"hyperparathyroidism":1,
"early identification":1,
"primary squamous cell carcinoma of the thyroid":1,
"Bethesda classification":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2020年1月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
